BioSpace News Archive

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the Journal of the American College of Cardiology: Heart Failure

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets.

TSO3 Inc. (TSX: TOS), (“TSO3" or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated April 3, 2018, were elected as directors of TSO3. In addition, all other proposals submitted by management were approved.

The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.

Knopp Biosciences LLC today announced the publication of a report that a Phase 2 study of dexpramipexole met its co-primary endpoints

Sokolov and Millon join a respected team of national and local experts from a broad range of healthcare sectors and community leaders in aiding Equality Health with strategic development, market insights and consulting.

First-Quarter Revenue of $494.0 Million

$1.6 billion transaction will bolster Lilly’s clinical portfolio with ARMO’s lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types

AstraZeneca today announced that Health Canada has approved Lynparza® (olaparib) tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting

American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches